Robert Langer: Edison of Medicine | Lex Fridman Podcast #105

Research Profile & Context

• Bob Langer is a professor at MIT and one of the most cited researchers in history (over 295,000 citations, H-index of 269).
• The interview was recorded prior to the COVID-19 pandemic, though his work later contributed to vaccine candidates and treatments for the virus.
• Langer has helped launch over 40 biotech companies with an estimated valuation of $23 billion.

Scientific Philosophy & History

• Langer compares the surprise element in magic to the discovery process in science, noting both involve witnessing the impossible.
• Early in his career, Langer and his advisor Judah Folkman faced significant rejection; a seminal paper on angiogenesis inhibitors was first rejected by Nature and accepted by Science, while a companion paper was rejected by Science and accepted by Nature.
• He characterizes the initial discovery of angiogenesis inhibitors (1976) as occurring in "the dark" due to a lack of biological understanding and existing techniques.
• It took 28 years and billions of dollars to bring the first angiogenesis inhibitor, Avastin, to FDA approval (2004).

Drug Delivery & Technology

• Angiogenesis: Langer's early work focused on developing polymer systems to slowly release substances that could stop blood vessel growth (inhibitors) or promote it.
• Polymers: Defined as plastic-like structures used to create controlled-release mechanisms for delivering molecules over months rather than days.
• Challenges: Key hurdles include targeting specific cells (e.g., cancer vs. healthy tissue), crossing biological barriers (e.g., blood-brain barrier), and achieving oral delivery for large molecules like insulin.
• Intelligent Systems: Langer envisions "smart" delivery systems that respond to physiological signals (e.g., releasing more insulin when glucose levels rise) without necessarily being full robots.
• AI Integration: Artificial intelligence is expected to assist in drug discovery by analyzing high-throughput chemical data to predict effective compounds and identify structural commonalities.

Tissue Engineering & Regenerative Medicine

• Concepts: Involves building organs or tissues from scratch using scaffolds (the "canvas"), various cell types (including stem cells), and potentially integrated electronic sensors.
• Current Status: FDA-approved engineered skin is currently used for burn victims and diabetic ulcers; clinical trials are active for blood vessels, hearing, paralysis, and eye conditions.
• Immune Rejection: Strategies to mitigate rejection include encapsulating cells to block immune attack, gene editing to make cells non-immunogenic, and using patient-derived cells.
• Organs on a Chip: Microfluidic devices that mimic human organ functions, serving as "canvas" structures for testing drugs and reducing reliance on animal testing.

Business & Institutional Strategy

• Patent System: Langer argues the patent system is essential to recoup the >$2 billion cost of drug development, despite acknowledging it can later impede accessibility.
• Cost Drivers: Human clinical trials (Phases I, II, and III) represent the most expensive and time-consuming phase of bringing a drug to market.
• Startup Success Formula: Success depends more on business acumen (strategic hiring, fundraising, regulatory strategy) than just scientific discovery.
• Decision Criteria: Selecting which drug to develop first involves evaluating market size, availability of animal models, clear clinical endpoints, competition, and reimbursement potential.
• Academic Funding: Langer expresses concern regarding the stability of "soft money" funding for basic research and the need for better societal investment in education and young researchers.

Future Outlook & Personal Insights

• Cancer Cure: Langer predicts a cure for cancer will eventually arrive through a combination of biological understanding (genetic/immunological mechanisms) and engineering (molecules/delivery systems), though it is not imminent.
• Longevity: He anticipates tissue engineering will improve quality of life and extend life spans moderately, but does not foresee radical increases in maximum human longevity within the next 10–20 years.
• CRISPR: He views CRISPR as a "beautiful idea" that leverages bacterial defense mechanisms, noting that stepwise applications (e.g., enhancing CAR-T cells) are more immediate than whole-body cures.
• Leadership: Langer prioritizes creating a lab environment where researchers are happy and motivated by the potential to positively impact the world.
• Legacy: He cites his students (nearly 1,000, with significant representation in national academies and as company CEOs) as his greatest professional accomplishment.
• Philanthropy: He suggests philanthropists should first define a concrete vision (e.g., treating disease vs. helping the developing world) before seeking out the best researchers.